What is Merck & Co.'s stock-based comp?

Merck & Co. (MRK) reported stock-based comp of $185M in Q1 2026.

How has Merck & Co.'s stock-based comp changed year-over-year?

Merck & Co.'s stock-based comp decreased by 5.1% year-over-year, from $195M to $185M.

What is the long-term trend for Merck & Co.'s stock-based comp?

Over 4 years (2021 to 2025), Merck & Co.'s stock-based comp has grown at a 14.4% compound annual growth rate (CAGR), from $479M to $820M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Merck & Co. MRK Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers SquibbBMY

$146M+1.4%

PfizerPFE

$272M+60.0%

Johnson & JohnsonJNJ

$300M+4.2%

Regeneron PharmaceuticalsREGN

$257.4M+0.7%

CytokineticsCYTK

$30.39M+29.1%

Phibro Animal HealthPAHC

$411K+130%

Other financials

Income statement

See full

Revenue$16.3B+4.9%

Gross profit$12.1B-0.2%

Net income-$4.2B-183%

EPS (diluted)-$1.72-186%

Balance sheet

See full

Cash & equivalents$5.4B-38.2%

Total debt$49.1B+35.8%

Total equity$45.9B-5.1%

Total assets$128.69B+11.8%

Cash flow

See full

Operating cash flow$3.9B+56.7%

CapEx$991.0M-25.4%

Free cash flow$2.9B+150%

Valuation

See full

Market cap$317.77B+57.6%

Enterprise value$361.47B+56.9%

P/E35.6×+23.3×

P/S4.8×+1.7×

Profitability

See full

Gross margin73.9%-2.5pp

Net margin13.6%-13.7pp

FCF margin21.5%-5.2pp

Returns & leverage

See full

Return on equity19%-20.3pp

Debt / equity1.1×+0.3×

Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Merck & Co.'s stock-based comp?: Merck & Co. (MRK) reported stock-based comp of $185M in Q1 2026.
How has Merck & Co.'s stock-based comp changed year-over-year?: Merck & Co.'s stock-based comp decreased by 5.1% year-over-year, from $195M to $185M.
What is the long-term trend for Merck & Co.'s stock-based comp?: Over 4 years (2021 to 2025), Merck & Co.'s stock-based comp has grown at a 14.4% compound annual growth rate (CAGR), from $479M to $820M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.